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ABSTRACT
Nosocomial infections caused by antibiotic-resistant bacteria are associated with high morbidity and
mortality worldwide. Most prevention strategies focus on cross-transmission, but the endemic state
inside the hospital is also maintained through the inﬂux of patients colonised or infected with antibiotic-
resistant bacteria, balanced by the efﬂux of colonised patients following discharge. Epidemiological
research has demonstrated that eradication can be achieved by preventing the inﬂux of resistant
bacteria. The presence of a central venous catheter and a history of methicillin-resistant Staphylococcus
aureus (MRSA) infection or colonisation are associated signiﬁcantly with methicillin-resistant staphylo-
coccal bacteraemia at admission. Previous antibiotic therapy and transfer from long-term care facilities
or nursing homes are associated with bacteraemia caused by methicillin-resistant coagulase-negative
staphylococci, while skin ulcer and cellulites are independent risk-factors for MRSA bacteraemia.
A scoring system using point values has been developed and validated to identify patients positive for
vancomycin-resistant enterococci at admission. Six variables were identiﬁed: age > 60 years (2 points);
hospitalisation in the previous year (3); use of two or more antibiotics during the previous 30 days (3);
transfer from another hospital or long-term care facility (3); a requirement for chronic haemodialysis (2);
and a previous history of MRSA infection (4). With a point score cut-off of ‡ 10, the speciﬁcity of this
prediction rule is 98%. Knowledge of variables identifying patients at high risk for being colonised or
infected with antibiotic-resistant bacteria may assist clinicians in targeting preventive measures and
streamlining the use of vancomycin. Current studies are analysing risk-factors for harbouring
multiresistant Gram-negative bacteria at hospital admission.
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INTRODUCTION
Nosocomial infections pose a signiﬁcant threat to
patients worldwide, with a recent report of 4%
excess mortality for infections associated with
medical care, and 23% mortality for post-opera-
tive septicaemia [1]. Most deaths associated with
nosocomial infections are caused by antibiotic-
resistant bacteria. European surveillance has
documented that methicillin-resistant Staphylococ-
cus aureus (MRSA), vancomycin-resistant enter-
ococci (VRE), and multidrug-resistant Gram-
negative bacteria are increasing rapidly in import-
ance [2]. In the USA, National Nosocomial
Infection Surveillance data demonstrated that
the frequencies of MRSA, methicillin-resistant
coagulase-negative staphylococci (MR-CoNS)
and VRE in intensive care units in 2002 were
57%, 89% and 27%, respectively [3].
An endemic state of nosocomial infections
resistant to antibiotics may be achieved by a
constant inﬂux of microorganisms (e.g., MRSA
and VRE) into the healthcare setting from newly
admitted patients who are colonised or infected
with antibiotic-resistant bacteria, followed by
cross-transmission among hospitalised patients,
with de-novo acquisition and efﬂux of antibiotic-
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resistant bacteria from the hospital into the
community following the discharge of patients.
In order to develop effective prevention strat-
egies, it is ﬁrst necessary to understand the
various components responsible for this endemic
state. Until now, most prevention strategies have
focused on the middle component, i.e., the pro-
duction of guidelines for antibiotic therapy and
prevention of cross-transmission among hospital-
ised patients, and between hospital staff and
patients. However, the inﬂux of antibiotic-resist-
ant bacteria into the healthcare setting may be a
more important factor in the establishment of
endemicity. In a cohort of patients with MRSA
and vancomycin-resistant enterococcal bacterae-
mia, stratiﬁed by day of hospitalisation, an
unexpectedly high number of cases were diag-
nosed within 48 h of hospitalisation [4]. A mathe-
matical model describing the transmission
dynamics of VRE demonstrated that eradication
could be achieved by prevention of this inﬂux [5].
The model demonstrated that, although 100%
compliance with hand washing or a 1:1 nurse to
patient ratio would decrease the overall preval-
ence of VRE in the unit substantially, the only
intervention that achieved complete eradication
of VRE from this patient population over time
was the prevention of inﬂux of VRE into the unit.
On the basis of these ﬁndings, it seems neces-
sary to deﬁne the epidemiological characteristics
of patients at higher risk for being infected or
colonised with antibiotic-resistant bacteria at
hospital admission. This would allow targeted
screening procedures and commencement of the
most appropriate empirical antibiotic therapy in
order to reduce the spread of antibiotic-resistant
infections and related mortality.
METHICILLIN-RESISTANT
COAGULASE-NEGATIVE
STAPHYLOCOCCI
Several studies, including the SENTRY pro-
gramme, which provides surveillance data from
the USA, Canada, Latin America and Europe
[3,6], have shown that CoNS are the third most
common pathogens recovered from positive
blood cultures of community or hospital origin,
with attributable mortality rates of up to 14%.
In order to elucidate the epidemiology of
bacteraemia caused by CoNS that was diagnosed
at hospital admission, two case-control studies
were performed [7]. The case–case-control study
design, which compares risk-factors among two
groups of cases and a control group of patients
who do not have the disease, was chosen to
address speciﬁcally the impact of previous anti-
biotic therapy on the risk of bacteraemia caused by
antibiotic-resistant pathogens. It has been shown
that comparing patients with antibiotic-resistant
and antibiotic-susceptible infections could lead to
overestimation of the role of antibiotic therapy [8].
Following logistic regression analysis, the pres-
ence of a central venous catheter (CVC), a history
of MRSA infection or colonisation in the previous
year, transfer from long-term care facilities or
nursing homes, and previous antibiotic therapy
were associated signiﬁcantly with bacteraemia
caused by MR-CoNS at hospital admission. The
strongest predictor was the presence of a CVC,
which increased the risk for bacteraemia by 15-
fold. All of the risk-factors identiﬁed seemed to be
associated with healthcare facilities. Fig. 1 shows
the probability of methicillin resistance among
patients with true coagulase-negative staphylo-
coccal bacteraemia at hospital admission and
during the entire period of hospitalisation. The
probability of methicillin resistance among CoNS
causing bacteraemia at hospital admission was
73%. After stratiﬁcation of patients according to
admission from the community vs. healthcare
facilities, the probability of methicillin resistance
among the isolates of CoNS was 62% in patients
coming from the community, and 84% in patients
coming from other healthcare facilities. Resistance
to methicillin was signiﬁcantly higher among
nosocomial isolates of CoNS (73% vs. 88%).
Isolates from patients with bacteraemia caused
by MR-CoNS at hospital admission were also
signiﬁcantly more likely to be susceptible to
gentamicin (63% vs. 44%), clindamycin (49% vs.
27%) and erythromycin (26% vs. 13%) than were
those from patients with nosocomial bacteraemia
caused by MR-CoNS. All isolates were susceptible
to vancomycin. The only risk-factor for methicillin-
susceptible coagulase-negative staphylococcal
bacteraemia was the presence of a CVC. Other
potential risk-factors, including residence in a
long-term care facility or nursing home, previous
antibiotic therapy or numerous hospitalisations,
all of which are associated commonly with anti-
biotic-resistant pathogens, were not associated
with methicillin-susceptible coagulase-negative
staphylococcal bacteraemia.
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Given the high prevalence of methicillin resist-
ance among patients with bacteraemia caused by
CoNS at hospital admission, further understand-
ing of the epidemiology of such bacteraemia
would require knowledge of the mechanisms of
dissemination of MR-CoNS, and the ability to
distinguish between endogenous and exogenous
acquisition. A better knowledge of the epidemio-
logical characteristics of MR-CoNS at hospital
admission would help clinicians in choosing
empirical therapy, in particular with regard to
the use of vancomycin.
METHICILLIN-RESISTANT S . AUREUS
Although considered previously to be purely a
nosocomial pathogen, recovered from hospital-
ised patients only, MRSA is now isolated with
increasing frequency at hospital admission [9].
These ‘community-acquired’ MRSA strains arise
from two different patient populations: ﬁrst,
patients with true community-acquired MRSA
strains that have emerged de novo from commu-
nity-based S. aureus strains in speciﬁc populations
(e.g., children, prison inmates and military per-
sonnel); and second, patients with healthcare-
associated strains that have been acquired during
a recent exposure to a healthcare setting or
following surgical procedures [10,11]. The latter
patient population is twice as likely to harbour
MRSA than are individuals without exposure to a
healthcare setting [12]. This changing epidemiol-
ogy has led to an increase in the number of
patients with MRSA infections or colonisation
diagnosed at hospital admission. A meta-analysis
of MRSA infections identiﬁed within 24–72 h
of hospitalisation documented a prevalence of
community-acquired MRSA infections, deﬁned as
patients with no known risk-factors for harbour-
ing MRSA, of £ 0.24% [13]. These true commu-
nity-acquired MRSA strains are associated
frequently with skin infections, particularly in
children, tend to be susceptible to more antibiot-
ics, and are genetically distinct from healthcare-
associated strains [14]. In elderly populations, two
prospective case-control studies derived risk
scores that estimated the likelihood of unknown
MRSA carriers at hospital admission [15], with
the risk-factors being recent antibiotic therapy,
in-hospital transfers, and hospitalisation within
the previous 2 years.
To better deﬁne risk-factors for healthcare-
associated MRSA bacteraemia in adult popula-
tions, a case-control study was performed [16].
Using logistic regression analysis, independent
risk-factors associated with MRSA bacteraemia at
hospital admission included a history of previous
MRSA colonisation or infection within 90 days,
the presence of a CVC, and skin ulcer or cellulitis
at hospital admission. To extend the clinical
application of the study results, a second analysis
was performed that excluded previous MRSA
colonisation or infection, since knowledge of this
may not always be available at the time of
hospital admission. In this second analysis,
although the presence of a CVC was once again
Pr
ob
ab
ilit
y 
of
 m
et
hi
cil
lin
 re
sis
ta
nc
e
Days of hospitalisation
0 7 14 21 28 40 60
62%
99%
Pts from healthcare facilities Pts from community
Fig. 1. Probability of methicillin-
resistant strains in patients (Pts)
with bacteraemia caused by coagu-
lase-negative staphylococci at hos-
pital admission. Adapted from
Tacconelli et al. [7].
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a risk-factor, previous hospitalisations, diabetes
mellitus and quinolone therapy were also associ-
ated with MRSA bacteraemia at hospitalisation
(Table 1). The differences between the two analy-
ses suggest that a previous history of MRSA
colonisation or infection may be an indicator of
the other risk-factors identiﬁed in the second
analysis, all of which have been recognised
previously to increase the likelihood of MRSA
being harboured [17].
The simple patient characteristics identiﬁed in
the above study can be obtained easily during the
clinical assessment of a patient at hospital admis-
sion, and can identify a subgroup of patients who
are at high risk of MRSA bacteraemia among all
the patients admitted from community settings or
who have recently had exposure to healthcare
intervention. Empirical use of vancomycin in this
group may be warranted when patients present
with symptoms and signs consistent with bacter-
aemia. This group of patients may also warrant
prompt institution of infection control interven-
tions to limit cross-transmission, since it is well-
documented that colonised patients are the chief
source of S. aureus in hospitals.
Another important factor related to MRSA
infections is the availability of a therapeutic agent
for the prevention of S. aureus colonisation.
Mupirocin is a topical antibacterial ointment that
has demonstrated efﬁcacy in eradicating coloni-
sation with S. aureus [18,19]. In contrast, its
efﬁcacy in preventing S. aureus infections is
controversial, especially following gastrointesti-
nal surgery and for transplant patients [20,21].
Discordant results among published studies, and
varying estimates of the risk reduction, may be
caused by differences in study design and patient
populations, including type of dialysis modality,
mupirocin regimen, and type and deﬁnition of
infection. There are also concerns regarding
the emergence of mupirocin resistance among
S. aureus isolates [22].
A systematic review of the English language
literature was performed to determine the overall
beneﬁt of mupirocin therapy in reducing the rate
of S. aureus infection among high-risk patients
requiring chronic haemodialysis and peritoneal
dialysis [23]. In the year 2000, 71% of dialysis units
reported at least one patient with an MRSA
infection [24]. Of even more concern are the recent
reports of S. aureus isolates resistant to vancomycin
and linezolid, which have been recovered from
chronic haemodialysis patients [25,26]. The fol-
lowing criteria were used in selecting studies for
inclusion: studies involving adults aged ‡ 18 years
who required haemodialysis or peritoneal dialysis;
randomised controlled clinical trials or cohort
studies; use of mupirocin therapy among the
treatment group, and a placebo or no therapy
among the control group; and a primary outcome
showing the difference in the rate of S. aureus
infections (bacteraemia, exit site infection or peri-
tonitis) between mupirocin-treated and -untreated
dialysis patients. In total, ten clinical studies were
evaluated, with 1212 patients in the treatment
group and 1233 in the control group. Overall,
mupirocin therapy reduced the risk of developing
S. aureus infection by 68% among all dialysis
patients (Fig. 2). In a subgroup analysis of different
dialysis modalities, the reduction in risk was 80%
for haemodialysis patients and 63% for peritoneal
dialysis patients, respectively. Analysis of other
types of S. aureus infection, including exit site
infection, peritonitis and bacteraemia, demonstra-
ted signiﬁcant reductions in risk among patients
receiving mupirocin therapy.
This meta-analysis quantiﬁed the beneﬁt of
mupirocin in preventing S. aureus infection in
dialysis patients. Nevertheless, the optimal stra-
tegy for using this topical antimicrobial agent
and minimising the emergence of resistance is
still unclear. Since patients often become recolo-
nised with S. aureus following initial treatment,
periodic screening, with application of mupiro-
cin for carriers, seems to be a reasonable strategy
which would target mupirocin for use with
high-risk patients and limit unnecessary use,
Table 1. Risk-factors associated with healthcare-associ-
ated bacteraemia caused by methicillin-resistant Staphylo-
coccus aureus (MRSA) within 24 h of hospitalisation,
including (ﬁrst model) and excluding (second model) a
history of previous MRSA infection or colonisation
Variables
Odds
ratio
95%
CI p
First model
Previous MRSA infection or colonisation 17.04 4.98–58.27 < 0.001
Cellulitis at hospital admission 4.27 1.52–11.94 0.006
Presence of a central venous catheter 3.30 1.71–6.38 < 0.001
Skin ulcers at hospital admission 3.12 1.37–7.11 0.007
Second model
Presence of a central venous catheter 3.24 1.76–5.97 < 0.001
Hospitalisation in the previous 6 months 2.01 1.11–3.65 0.02
Quinolone therapy in the previous 30 days 1.99 1.07–3.69 0.02
Diabetes mellitus 1.84 1.05–3.22 0.03
Adapted from Tacconelli et al. [16].
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thereby decreasing the emergence of resistance.
Future studies in other high-risk populations are
needed.
VANCOMYCIN-RESISTANT
ENTEROCOCCI
VRE have become endemic in numerous health-
care institutions in Europe and the USA [27,28]. A
1-day cross-sectional study in a 1700-bed univer-
sity hospital in Rome, with 60 000 admissions
annually, found 25 patients colonised with
VRE ⁄ 1000 admissions [29]. The recent isolation
of vancomycin-resistant S. aureus strains, result-
ing from the transfer of vancomycin resistance
genes from VRE to S. aureus [30,31], emphasises
the urgent need to prevent de-novo acquisition of
VRE. Impeding the inﬂux of VRE into a healthcare
institution would require a programme of active
surveillance, using cultures to detect gastrointes-
tinal colonisation with VRE among all patients
admitted to the hospital. However, given the low
prevalence of VRE at admission, it would not be
economically feasible to screen all newly admitted
patients.
To identify the characteristics of patients at
high risk for colonisation with VRE, a two-centre,
6-year study of patients harbouring VRE at
hospital admission was performed [32]. From this
analysis, a clinical prediction rule was developed
to indicate which high-risk subgroup of newly
admitted patients required screening for VRE and
contact isolation. The prediction rule was then
validated using a separate cohort of high-risk
patients. Six variables, easily obtainable during
the initial clinical assessment of patients, were
identiﬁed and weighted scores were applied. The
variables identiﬁed were: age > 60 years; hospi-
talisation during the previous year; use of two or
more antibiotics during the previous 30 days;
transfer from another hospital or long-term care
facility; a requirement for chronic haemodialysis;
and a previous history of MRSA colonisation or
infection. To develop the prediction rule, a scor-
ing system using point values was employed.
The natural logarithm of the odds ratio of each
risk-factor selected by the logistic regression
model was multiplied by two and rounded off
to the nearest integer (Table 2). With a point score
cut-off of ‡ 10, the speciﬁcity of this prediction
rule was 98% in the combined derivation and
validation cohorts (Fig. 3). The predictive values
were similar in both cohorts of study patients
from two different hospitals, further validating
the accuracy of the prediction rule. These results
Risk ratio
0.043219 1 23.1382
Study
 % Weight
 Risk ratio
 (95% CI)
 0.38 (0.04, 3.25) Boelaert, 1989   1.6
 0.21 (0.11, 0.40) Perez, 1993  12.1
 0.23 (0.08, 0.68) Boelaert, 1993   5.8
 0.47 (0.33, 0.66) Mup. Group, 1996  20.5
 0.19 (0.07, 0.55) Kluytmans, 1996   5.9
 0.25 (0.14, 0.43) Thodis1, 1998  14.0
 0.36 (0.18, 0.74) Thodis2, 1998  10.5
 0.15 (0.06, 0.41) Sesso, 1998   6.4
 0.52 (0.34, 0.79) Crabtree, 2000  18.0
 0.41 (0.13, 1.29) Casey, 2000   5.2
 0.32 (0.24, 0.43) Overall (95% CI)
Fig. 2. Risk ratio and 95% CI for
mupirocin vs. placebo or no pro-
phylaxis in clinical trials for preven-
tion of Staphylococcus aureus
infections in the dialysed patient
population. Adapted from Taccon-
elli et al. [23].
Table 2. Risk index for vancomycin-resistant enterococci
at hospital admission
Risk-factor
Points
score
MRSA colonisation or infection
within the previous year
4
Chronic haemodialysis 3
Long-term facility ⁄hospital transfer 3
Exposure to two or more antibiotics
within the previous 30 days
3
Hospitalisation within the previous year 3
Age > 60 years 2
MRSA, methicillin-resistant Staphylococcus aureus.
Adapted from Tacconelli et al. [32].
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suggest that use of this prediction rule (i.e., a
points score of ‡ 10) with patients at hospital
admission would identify a large proportion of
patients harbouring VRE correctly. Fig. 4 displays
the positive and negative predictive values for the
scoring system when comparing patients with
VRE at hospital admission and patients without
VRE in derivation and validation cohorts.
Screening programmes for detecting VRE
among patients who are already hospitalised
have been used extensively [33,34]. These pro-
grammes are based on the important premise that
for every patient from whom VRE are recovered
in clinical cultures, there are many more patients
who have unrecognised colonisation with VRE
[35]. Tremendous beneﬁt from screening pro-
grammes has been achieved by decreasing the
overall prevalence of VRE and the number of
infections with VRE over time [36,37]. The cost-
effectiveness of this approach has also been
demonstrated [35,36]. The risk score approach
appears to be a novel and diagnostically accurate
strategy for potentially preventing dissemination
of VRE from the reservoir of VRE entering the
hospital, thereby ultimately decreasing cross-
transmission and de-novo acquisition of VRE.
CONCLUSIONS
Preventing transmission of antibiotic-resistant
bacteria is important, since these infections are
associated with considerable morbidity and mor-
tality, and excess hospital costs. Rising rates of
methicillin-resistant staphylococcal infections also
result in greater use of vancomycin, with an
increased risk of emergence of glycopeptide-
resistant pathogens. Knowledge of the variables
that identify patients at higher risk for being
carriers, or for being infected with antibiotic-
resistant bacteria, may assist clinicians in target-
ing preventive measures and streamlining the use
of vancomycin.
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Fig. 3. Receiver operating character-
istic curves for the sensitivity and
speciﬁcity of the scoring system
used to compare patients with
vancomycin-resistant enterococci at
hospital admission with patients
without vancomycin-resistant
enterococci in the derivation cohort
(dotted line), the validation cohort
(dashed line) and the combined
cohort (continuous line). Adapted
from Tacconelli et al. [32].
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Fig. 4. Positive and negative predic-
tive values of the combined cohorts,
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Until now, most prevention strategies in hos-
pitals have targeted the middle component of the
endemic state, i.e., cross-transmission among
hospitalised patients. However, many studies
have now shown the importance of the inﬂux of
antibiotic-resistant bacteria into hospitals. Epide-
miological studies are therefore necessary to
understand the variables associated with a high
risk for being colonised or infected with antibi-
otic-resistant bacteria at hospital admission. In
particular, the clinical prediction rule described
above for VRE provides an additional strategy for
targeting the inﬂux of the microorganism into a
hospital by identifying patients harbouring VRE
at hospital admission. This strategy would limit
the potential for dissemination of VRE from these
unrecognised reservoirs at the start of their period
of hospitalisation, as opposed to other strategies,
in which screening programmes target patients
already hospitalised. Although the inﬂux of VRE
into a hospital would not change, the beneﬁt of
early detection is that it would reduce the time
that such unrecognised carriers might have to
disseminate VRE. The spread of antibiotic-resist-
ant bacteria within a hospital is a complex
process. Elucidating and intervening at all stages
of the transmission chain may allow the use of
more weapons to win this ﬁght.
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